No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	AU-011 Sensitive: B - Late Trials AU-011 Sensitive : B	AU-011 Sensitive: B - Late Trials AU-011 Sensitive : B
EGFR mutation	Glioblastoma	EGFR mutation	Glioblastoma	verteporfin Sensitive: C2 – Inclusion Criteria verteporfin Sensitive : C2	verteporfin Sensitive: C2 – Inclusion Criteria verteporfin Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	bortezomib + verteporfin Sensitive: D – Preclinical bortezomib + verteporfin Sensitive : D	bortezomib + verteporfin Sensitive: D – Preclinical bortezomib + verteporfin Sensitive : D
EGFR amplification	Glioblastoma	EGFR amplification	Glioblastoma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
NF2 mutation	Mesothelioma	NF2 mutation	Mesothelioma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
LATS1 mutation	Mesothelioma	LATS1 mutation	Mesothelioma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
LATS2 mutation	Mesothelioma	LATS2 mutation	Mesothelioma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
RASSF7 amplification	Mesothelioma	RASSF7 amplification	Mesothelioma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
TP53 deletion + RB1 deletion + CTSK expression	Osteosarcoma	TP53 deletion + RB1 deletion + CTSK expression	Osteosarcoma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	binimetinib + STA-4783 Sensitive: D – Preclinical binimetinib + STA-4783 Sensitive : D	binimetinib + STA-4783 Sensitive: D – Preclinical binimetinib + STA-4783 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	binimetinib + STA-4783 Sensitive: D – Preclinical binimetinib + STA-4783 Sensitive : D	binimetinib + STA-4783 Sensitive: D – Preclinical binimetinib + STA-4783 Sensitive : D
GNA11 mutation	Uveal Melanoma	GNA11 mutation	Uveal Melanoma	STA-4783 Sensitive: D – Preclinical STA-4783 Sensitive : D	STA-4783 Sensitive: D – Preclinical STA-4783 Sensitive : D
GNAQ mutation	Uveal Melanoma	GNAQ mutation	Uveal Melanoma	STA-4783 Sensitive: D – Preclinical STA-4783 Sensitive : D	STA-4783 Sensitive: D – Preclinical STA-4783 Sensitive : D
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	STA-4783 Resistant: D – Preclinical STA-4783 Resistant : D	STA-4783 Resistant: D – Preclinical STA-4783 Resistant : D
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	lorlatinib + verteporfin Sensitive: D – Preclinical lorlatinib + verteporfin Sensitive : D	lorlatinib + verteporfin Sensitive: D – Preclinical lorlatinib + verteporfin Sensitive : D

Reactive oxygen species stimulant

Reactive oxygen species stimulant

Associations(16)

Associations
(16)